ANGPT1 and COVID-19: Recently, Lázaro et al. proved that an even more augmented concentration of VCAM-1, with a high acute-lung-injury-specific angiopoeitin-2/angiopoietin-1 ratio, predicted unfavourable outcomes with a good efficacy in critically ill COVID-19 patients with diabetes mellitus [53].